ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
Authors:
Open Access
- 12 March 2013
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 108 (6) , 1238-1244
Abstract
Background: Methods: Results: Conclusion:Keywords
This publication has 32 references indexed in Scilit:
- Immunogenic death of colon cancer cells treated with oxaliplatinOncogene, 2009
- Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3Journal of Clinical Oncology, 2009
- Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803Journal of Clinical Oncology, 2009
- Platinum Resistance: The Role of DNA Repair PathwaysClinical Cancer Research, 2008
- Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiationBritish Journal of Cancer, 2008
- Molecular Prognostic Markers in Locally Advanced Colon CancerClinical Colorectal Cancer, 2007
- Current status of excision repair cross complementing-group 1 (ERCC1) in cancerCancer Treatment Reviews, 2007
- Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07Journal of Clinical Oncology, 2007
- Molecular mechanisms of resistance and toxicity associated with platinating agentsCancer Treatment Reviews, 2007
- DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant ChemotherapyNew England Journal of Medicine, 2006